Patents Assigned to OMNICYTE
  • Fusion proteins comprising modified alpha virus surface glycoproteins and tumor associated antigen and methods thereof
    Patent number: 12133885
    Abstract: The present disclosure relates to fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more tumor specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more viral specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins. It also relates to methods to activate the immune system in cancer patients to infiltrate and kill tumor cells or cells infected with a latent virus. The present disclosure provides a platform technology that elicits a faster, broader and stronger immune response using the fusion proteins.
    Type: Grant
    Filed: October 13, 2022
    Date of Patent: November 5, 2024
    Assignee: OMNICYTE
    Inventors: Peter Leonardi, Elin Martina Pola, Jeffrey Babad
  • Fusion proteins comprising modified alpha virus surface glycoproteins and tumor associated antigen and methods thereof
    Patent number: 11471518
    Abstract: The present disclosure relates to fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more tumor specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more viral specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins. It also relates to methods to activate the immune system in cancer patients to infiltrate and kill tumor cells or cells infected with a latent virus. The present disclosure provides a platform technology that elicits a faster, broader and stronger immune response using the fusion proteins.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: October 18, 2022
    Assignee: OMNICYTE
    Inventors: Peter Leonardi, Elin Martina Pola, Jeffrey Babad
  • Fusion proteins comprising modified alpha virus surface glycoproteins and tumor associated antigen and methods thereof
    Patent number: 10660948
    Abstract: The present disclosure relates to fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more tumor specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more viral specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins. It also relates to methods to activate the immune system in cancer patients to infiltrate and kill tumor cells or cells infected with a latent virus. The present disclosure provides a platform technology that elicits a faster, broader and stronger immune response using the fusion proteins.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: May 26, 2020
    Assignee: OMNICYTE
    Inventors: Peter Leonardi, Elin Martina Pola, Jeffrey Babad